<DOC>
	<DOCNO>NCT00520741</DOCNO>
	<brief_summary>The objective historical-controlled trial demonstrate efficacy safety conversion Lacosamide monotherapy subject Partial-onset Seizures withdraw 1 2 market antiepileptic drug .</brief_summary>
	<brief_title>Trial Demonstrate Efficacy Safety Conversion Lacosamide Monotherapy Partial-onset Seizures</brief_title>
	<detailed_description>Sudden unexplained death epilepsy report epilepsy patient . A causal relationship administration antiepileptic drug establish . The important know risk factor sudden unexplained death epilepsy ( SUDEP ) occurrence frequency generalize tonic-clonic seizure ( GTCS ) . Twenty-seven patient GTCS enrol conversion monotherapy study . In study , two patient GTCS SUDEP . Due potential increase risk SUDEP patient GTCS trial setting , 1 remain patient GTCS withdrawn study .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject diagnosis Epilepsy Simple Partial Seizures ( motor component ) Complex Partial Seizures ( without secondary generalization ) Must experience 2 40 seizure per 28day period Stable dose 1 2 market antiepileptic drug Second Antiepileptic Drug ( AED ) must less equal 50 % minimum recommend maintenance dose per USA product label screen Subject history primary generalize unclassified seizure Seizure disorder primarily characterize isolated aura History status epilepticus Seizures uncountable due clustering Has great 5 seizures/day Subjects take Benzodiazepines , Phenobarbital Primidone Subject Vagus Nerve Stimulation ( VNS ) Significant medical psychiatric condition History alcohol drug abuse History Ethosuximide use , Felbamate use 1994 Vigabatrin use 1997</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Partial Onset Seizures</keyword>
	<keyword>Lacosamide</keyword>
	<keyword>Monotherapy</keyword>
	<keyword>Vimpat</keyword>
</DOC>